![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Joincare will develop and commercialize TG-1000, a novel pan-influenza antiviral by interrupting viral replication and transmission via a cap-snatching mechanism, revealing efficacy against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses, in china.
Lead Product(s): TG-1000
Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000
Highest Development Status: Phase II Product Type: Small molecule
Recipient: TaiGen Biotechnology
Deal Size: Undisclosed Upfront Cash: $2.9 million
Deal Type: Licensing Agreement March 22, 2023